Inventor · disambiguated record
Michael M. Miller
Also filed as: MILLER II MICHAEL MATTHEW · MILLER MICHAEL · MILLER MICHAEL M · MILLER MICHAEL MATTHEW
21 granted patents·5 pending applications·184 citations·filing 2006–2024
95Inventor score
Top patents by PatentIndex Score
26 records- 0196US9308236B2Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Apr 12, 2016·51 cites·5 claims
- 0295US9879046B2Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 30, 2018·17 cites·12 claims
- 0393US10143746B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Dec 4, 2018·9 cites·17 claims
- 0493US10047103B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Aug 14, 2018·11 cites·22 claims
- 0592US10822343B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 3, 2020·4 cites·15 claims
- 0692US10428077B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Oct 1, 2019·8 cites·9 claims
- 0792US9850283B2Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 26, 2017·12 cites·1 claims
- 0890US9688695B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jun 27, 2017·11 cites·51 claims
- 0988US9944678B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 17, 2018·8 cites·2 claims
- 1087US10450347B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 22, 2019·6 cites·23 claims
- 1187US10358463B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jul 23, 2019·7 cites·15 claims
- 1287US7790770B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Sep 7, 2010·10 cites·25 claims
- 1386US9862730B2Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 9, 2018·5 cites·11 claims
- 1486US9518064B2Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Dec 13, 2016·5 cites·18 claims
- 1585US2025002497A1Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1684US10538555B2Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 21, 2020·8 cites·3 claims
- 1784US7888376B2Heterocyclic CETP inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Feb 15, 2011·8 cites·17 claims
- 1882US11492375B2Cyclic peptide immunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 8, 2022·2 cites·16 claims
- 1980US12084452B2Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 10, 2024·0 cites·6 claims
- 2071US8304403B2Heterocyclic CETP inhibitorsSALVATI MARK E·Filed 2010·Granted Nov 6, 2012·2 cites·17 claims
- 2157US2017369530A1Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 2251US8642576B2Heterocyclic CETP inhibitorsSALVATI MARK E·Filed 2012·Granted Feb 4, 2014·0 cites·14 claims
- 2350US9605022B2Macrocyclic compounds for inhibition of inhibitors of apoptosisENSEMBLE THERAPEUTICS CORP·Filed 2013·Granted Mar 28, 2017·0 cites·11 claims
- 2444US2016222060A1ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 2543US2014135270A1Macrocyclic compounds for inhibition of inhibitors of apoptosisENSEMBLE THERAPEUTICS CORP·Filed 2013·Application pending·0 cites
- 2642US2014309265A1Macrocyclic compounds for inhibition of inhibitors of apoptosisENSEMBLE THERAPEUTICS·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael M. Miller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →